MedTrace Logo

Effectiveness of Sugammadex on Muscle Relaxant Reversal in Preterm Neonates

NCT04566796 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-09-28

No results posted yet for this study

Summary

The primary aim of the work is to compare the efficacy of Sugammadex and neostigmine in reversing rocuronium-induced muscle relaxation to reach complete recovery of neuromuscular block (TOF ratio≥ 0.9) in preterm neonates.

The secondary aim is to evaluate the safety of using Sugammadex in preterm neonates and to detect any complications that may occur in this age group.

Conditions

  • Sugammadex

Interventions

DRUG

Sugammadex

give 2 mg/ kg as muscle reversal drug in premature infants

DRUG

Neostigmine

give 0.02 mg/ kg atropine and 0.05 mg/kg neostigmine IV. as muscle reversal drug in premature infants

Sponsors & Collaborators

  • Alexandria University

    lead OTHER

Principal Investigators

  • Ahmed M Elshafie · Alexandria University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Max Age
28 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-11
Primary Completion
2021-02-28
Completion
2021-02-28

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04566796 on ClinicalTrials.gov